PPM-3
Based on 1 Customer Validation
PPM-3 is a highly selective ERK5 PROTAC degrader that mediates the degradation of ERK5 protein by recruiting VHL. PPM-3 inhibits ERK5 kinase activity with an IC50 of 62.4 nM. PPM-3-mediated ERK5 degradation exhibits a hook effect. PPM-3 exerts no significant direct inhibitory effect on the proliferation and migration of cancer cells. PPM-3 can be used in studies related to macrophage polarization and tumor immunity.
(Pink: ERK5 ligand (HY-184975); Blue: VHL ligand (HY-112078); Black: linker).
For research use only. We do not sell to patients.
- CAS No.: 3032388-42-1
- Formula: C54H69N11O6S
- Molecular Weight:1000.26
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
ERK5 62.4 nM (IC50) |
In Vitro
PPM-3 potently inhibits ERK5 kinase activity with an IC50 of 62.4 nM[1].
When tested in a cell-free system, PPM-3 (0.5 μM) exhibits excellent kinase selectivity for ERK5 compared with more than 300 other kinases[1].
PPM-3 effectively reduces ERK5 protein levels in an initial degradation activity comparison assay in A375 cells, with a DC50 of approximately 17 nM, and exhibits the highest ERK5 degradation activity among PPM-3, PPM-4 and PPM-5[1].
PPM-3 (6-500 nM; 12 h) selectively degrades ERK5 but does not degrade LRRK2, BRD4 or DCLK1 in A375 melanoma cells[1].
PPM-3 (200 nM; 12 h) induces ERK5 degradation in A375 cells. Pre-incubation with MG132 (HY-13259) (1 μM) or MLN4924 (HY-70062) (1 μM) for 1 h blocks the downregulation of ERK5, supporting that PPM-3-mediated ERK5 degradation depends on the proteasome/E3 ubiquitination-related pathway[1].
PPM-3 (12 h) is a potent ERK5 degrader active against six cancer cell lines, with DC50 values ranging from 5.6 nM (HCT116) to 41.4 nM (A375) and a maximum degradation efficiency of 86.7-94.7%[1].
PPM-3 (72 h) does not reduce the cell viability of H1975, HepG2, MDA-MB-231, PC-3, HCT116, or A375 cancer cells[1].
PPM-3 (0.01-1 μM; 24 h) does not affect the migration of A375 or HCT116 cancer cells[1].
PPM-3 (10-1000 nM; 24 h) does not reduce ERK5 mRNA levels in A375 cells, indicating that the decrease in ERK5 protein is not caused by the downregulation of ERK5 transcription[1].
PPM-3 (6-500 nM; 12 h) selectively degrades ERK5 in A375 cells, with no significant effect on the protein levels of LRRK2, BRD4, and DCLK1[1].
PPM-3 (200 nM) begins to induce ERK5 degradation in A375 cells within 2-4 h, reaches its maximum degradation effect at 12 h, and this effect is maintained for at least 72 h[1].
PPM-3 (12 h) effectively degrades ERK5 in H1975, HepG2, MDA-MB-231, PC-3, HCT116, and A375 cells, with DC50 values of 11.5, 13.7, 22.7, 23.5, 5.6, and 41.4 nM, and DCmax values of 94.7%, 92.7%, 86.7%, 89.4%, 88.9%, and 91.4%, respectively[1].
PPM-3 (72 h) exhibits no significant direct antiproliferative effect within the concentration range that effectively degrades ERK5 in H1975, HepG2, MDA-MB-231, PC-3, HCT116, and A375 cells[1].
Combined exposure to PPM-3 (200 nM; 72 h) with Dabrafenib (HY-14660), Vemurafenib (HY-12057), Trametinib (HY-10999), Mirdametinib (HY-10254), or GDC-0994 (HY-15947) does not significantly alter the effects of these RAF, MEK1/2, or ERK1/2 inhibitors on the viability of A375/HCT116 cells[1].
PPM-3 (0.5 μM) exerts no significant effect on the colony formation of A375/HCT116 cells grown directly under normal culture conditions. However, conditioned medium from M0 or M2 macrophages treated with PPM-3 reduces tumor cell colony formation and attenuates the promoting effect of M2-conditioned medium on the colony growth of A375 and HCT116 cells[1].
PPM-3 (0.5 μM; pre-incubation for 0.5 h followed by the addition of 1 μg/mL LPS (HY-D1056) for 24 h) consistently and effectively reduces ERK5 and decreases LPS-induced IL-6 and IL-10 release in THP-1 cells[1].
PPM-3 (0.5 μM; 48 h) induces morphological changes in macrophages in PMA (HY-18739)-induced THP-1-derived macrophages, and reduces the proportion of CD206-positive macrophages from 53.4% in the control group to 41.3%, supporting its inhibitory effect on M2 macrophage differentiation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A375 melanoma cells
-
Concentration:PPM-3: 200 nM; MG132: 1 μM; MLN4924: 1 μM
-
Incubation Time:MG132/MLN4924 preincubation: 1 h; PPM-3: 12 h
-
Result:Induced ERK5 protein degradation.
MG132 preincubation prevented ERK5 downregulation.
MLN4924 preincubation prevented ERK5 downregulation.
-
Cell Line:A375 melanoma cells
-
Concentration:10, 100, 1000 nM
-
Incubation Time:12 h
-
Result:Did not reduce ERK5 mRNA levels.
-
Cell Line:A375, HCT116
-
Concentration:0.01, 0.1, 1 μM
-
Incubation Time:24 h
-
Result:Did not evidently alter tumor-cell migration.
-
Cell Line:A375 and HCT116 cancer cells
-
Concentration:200 nM
-
Incubation Time:72 h
-
Result:Did not evidently alter the cell-viability effects of the tested RAF, MEK1/2, or ERK1/2 inhibitors.
-
Cell Line:A375
-
Concentration:6-500 nM
-
Incubation Time:12 h
-
Result:Selectively reduced ERK5 protein levels.
Did not evidently alter LRRK2 protein levels.
Did not evidently alter BRD4 protein levels.
Did not evidently alter DCLK1 protein levels.
-
Cell Line:A375
-
Concentration:0.04-30 μM
-
Incubation Time:12 h
-
Result:Increased ERK5 degradation as concentration increased up to approximately 1.1 μM.
Showed declining degradation activity at concentrations above approximately 1.1 μM, demonstrating a hook effect.
-
Cell Line:THP-1
-
Concentration:PPM-3: 0.5 μM; LPS: 1 μg/mL
-
Incubation Time:PPM-3 preincubation: 0.5 h; LPS: 24 h
-
Result:Reduced ERK5 protein levels in the presence of LPS.
Chemical Information
-
CAS No. 3032388-42-1
-
Appearance Solid
-
Molecular Weight 1000.26
-
Formula C54H69N11O6S
-
Color White to off-white
-
SMILES
O=C(C1=CC=CC=C1N(C)C2=NC(NC3=CC=C(C=C3OC)N4CCN(CC4)CCCCCCC(N[C@@H](C(C)(C)C)C(N5C[C@@H](C[C@H]5C(N[C@H](C6=CC=C(C=C6)C7=C(N=CS7)C)C)=O)O)=O)=O)=NC=C28)N8C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Primary monocyte-to-macrophage differentiation
Primary human monocytes can be differentiated ex vivo into monocyte-derived macrophages by culturing purified blood monocytes for approximately 5-7 days in macrophage-supporting cytokine conditions; M-CSF commonly yields CD14^high/CD163^high macrophages, while GM-CSF yields a phenotypically distinct macrophage population, so the cytokine condition should be chosen according to the downstream model. The readout of successful differentiation is a combined change in morphology, adherence, surface phenotype, and function: differentiated macrophages become adherent, enlarge, acquire macrophage-associated markers such as CD14, CD68, CD163, CD206, or HLA-DR depending on culture condition, and show increased phagocytic capacity compared with starting monocytes.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)